Gabriele Hansen / Manfred Eigen Campus
Essener Bogen 7
PHONE: +49 40 / 56081-0
FAX: +49 40 / 56081-222
NUMBER OF EMPLOYEES: 2600
FOUNDING YEAR: 1993
Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, foundations and venture capitalists. Drug discovery solutions are provided in form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of innovative drug candidates and consulting arrangements. The Company operates worldwide and has leading scientific experts, state-of-the-art technologies as well as key therapeutic expertise in the areas of neuronal diseases, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. By leveraging this expertise, Evotec intends to develop best-in-class and first-in-class differentiated therapeutics on its systematic, unbiased and comprehensive infrastructure.
Evotec has long-term discovery alliances with partners including Bayer, Boehringer Ingelheim, Celgene, CHDI, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda, UCB and others. In addition, the Company has existing development partnerships and product candidates both in clinical and pre-clinical development.
These include partnerships e.g. with e.g. with Sanofi in the field of diabetes, with Bayer in the fields of endometriosis and chronic cough, and with Celgene in the areas of neurodegenerative diseases and oncology.
Evotec is built on integrated drug discovery know-how of over 25 years and is a leading player in the drug discovery field. The Company’s headquarters are located in Hamburg, Germany. Additional major operating sites exist in Abingdon and Manchester, UK; Göttingen and Munich, Germany, Branford, Princeton, Watertown and USA as well as Lyon and Toulouse, France, Verona, Italy and Basel, Switzerland. Evotec has more than 2,600 employees worldwide.